Scholarlink

Background <p>Although tyrosine kinase inhibitors (TKIs) have significantly improved survival outcomes in patients with anaplastic lymphoma kinase (<i>ALK</i>)-rearranged non-small cell lung cancer (NSCLC), the efficacy of current TKIs for emerging <i>ALK</i> rearrangement subtypes warrants further investigation, particularly with the advancements in genomic sequencing technologies.</p> Methods <p>We retrospectively analyzed 118 NSCLC patients with <i>ALK</i> rearrangements identified by next-generation sequencing (NGS) from January 2015 to April 2024. Among these, 89 patients who received first-line <i>ALK</i>-TKIs were assessed to determine therapeutic outcomes based on <i>ALK</i> rearrangement subtypes.</p> Results <p>Among 118 NSCLC patients, 36 (30.5%) harbored nonreciprocal/reciprocal translocations, 73 (61.9%) carried solitary <i>EML4-ALK</i> fusion, and 9 (7.6%) had solitary non-<i>EML4-ALK</i> fusions. Of the 89 patients treated with first-line TKIs, 60 (67.4%) had solitary 3’-<i>ALK</i> fusions, whereas 29 (32.6%) exhibited nonreciprocal/reciprocal <i>ALK</i> translocations. Compared with patients harboring solitary 3’-<i>ALK</i> fusions, those with nonreciprocal/reciprocal translocations experienced significantly shorter median progression-free survival (mPFS) (15.6 vs. 31.1&#xa0;months; HR = 1.805; <i>P</i> = 0.048), although no significant difference in median overall survival (mOS) was observed (66.6 vs. 75.7&#xa0;months; HR = 1.162; <i>P</i> = 0.714). Additionally, TP53 mutations were the most common co-occurring alterations in both groups, with no significant difference in frequency (<i>P</i> = 0.650).</p> Conclusions <p>Nonreciprocal/reciprocal ALK translocations represent an independent adverse prognostic factor for ALK-positive NSCLC patients compared with solitary 3′-ALK fusions. However, their poorer prognosis does not appear to be directly associated with TP53 co-mutations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Beyond ALK fusion positivity: structural complexity as a prognostic indicator in first-line ALK-TKI therapy

  • 期刊论文

  • 发表日期：

    2025年11月17日

查看全文
  • Dujiang Liu,
  • Kaibo Ding,
  • Linjing Zhou,
  • Xinyue Li,
  • Yanjun Xu

摘要

Background

Although tyrosine kinase inhibitors (TKIs) have significantly improved survival outcomes in patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC), the efficacy of current TKIs for emerging ALK rearrangement subtypes warrants further investigation, particularly with the advancements in genomic sequencing technologies.

Methods

We retrospectively analyzed 118 NSCLC patients with ALK rearrangements identified by next-generation sequencing (NGS) from January 2015 to April 2024. Among these, 89 patients who received first-line ALK-TKIs were assessed to determine therapeutic outcomes based on ALK rearrangement subtypes.

Results

Among 118 NSCLC patients, 36 (30.5%) harbored nonreciprocal/reciprocal translocations, 73 (61.9%) carried solitary EML4-ALK fusion, and 9 (7.6%) had solitary non-EML4-ALK fusions. Of the 89 patients treated with first-line TKIs, 60 (67.4%) had solitary 3’-ALK fusions, whereas 29 (32.6%) exhibited nonreciprocal/reciprocal ALK translocations. Compared with patients harboring solitary 3’-ALK fusions, those with nonreciprocal/reciprocal translocations experienced significantly shorter median progression-free survival (mPFS) (15.6 vs. 31.1 months; HR = 1.805; P = 0.048), although no significant difference in median overall survival (mOS) was observed (66.6 vs. 75.7 months; HR = 1.162; P = 0.714). Additionally, TP53 mutations were the most common co-occurring alterations in both groups, with no significant difference in frequency (P = 0.650).

Conclusions

Nonreciprocal/reciprocal ALK translocations represent an independent adverse prognostic factor for ALK-positive NSCLC patients compared with solitary 3′-ALK fusions. However, their poorer prognosis does not appear to be directly associated with TP53 co-mutations.